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Patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) are often treated with induction
chemotherapy or chemoradiotherapy, but to date without major impact on survival. The combination of cisplatin–5-fluorouracil
(5-FU) (PF) has been used as standard induction therapy; however, poor patient survival has stimulated investigation into new agents
with potential activity in SCCHN. Docetaxel has significant single-agent activity in SCCHN and has been investigated in combination
with PF regimens as induction therapy. The results of six phase II studies of docetaxel–PF regimens (TPF) as induction in locally
advanced SCCHN patients are reviewed and reported. Consistently, high 2-year survival rates and overall response rates were
demonstrated across the phase II trials in the range 42–82 and 71–100%, respectively. The toxicity profile seen with TPF-based
regimens was acceptable. The primary toxicity was neutropenia, which together with gastrointestinal complaints accounted for the
majority of adverse events. Given the encouraging phase II experience with TPF-based regimens, two large-scale phase III studies
comparing TPF-based regimens with standard PF regimens are underway. The results have significant potential for validating the
findings of the phase II studies, demonstrating improved survival and overall response of patients treated with docetaxel-based
induction chemotherapy.
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Squamous cell cancer of the head and neck (SCCHN) is a
significant international problem. Cancer specific to the mouth
and pharynx is the sixth most common cancer worldwide, and the
third most common cancer among men in developing countries
(Johnson, 2001). Men are at higher risk of developing these cancers
and are affected 2–3 times as often as women in industrialised
countries. There are approximately 400000 new cases of SCCHN
projected annually (Parkin and Muir, 1992). Most SCCHN cases
are locally advanced at presentation, with up to 75% of patients
having stage III–IV, M0 disease (Dreyfuss et al, 1996; Parker,
1996). Stage of disease at diagnosis is regarded as the single most
important prognostic factor (Forastiere, 2000). Stage I–II SCCHN
is often curable with either surgery or radiotherapy, but it is
generally accepted that treatment of locally advanced SCCHN
should involve a combined modality approach (Forastiere, 2000).
Surgery and/or radiotherapy remain cornerstones of therapy in
patients with locally advanced SCCHN. However, induction
chemotherapy and chemoradiotherapy are now firmly integrated
in locoregional care. Controlled studies have established cisplatin
and continuous-infusion 5-fluorouracil (5-FU) as the standard
induction regimen for unresectable locally advanced SCCHN
patients (Paccagnella et al, 1994; Lefebvre et al, 1996; Domenge
et al, 2000; Pignon et al, 2000). Up to 40% of chemonaı ¨ve locally
advanced SCCHN patients treated with cisplatin–5-FU (PF) have
been reported to achieve a complete response, with an overall
response rate (ORR) in the range of 85% (Schantz et al, 2001). The
main toxicities associated with PF-induction therapy are haema-
tological, digestive and mucositis with the majority of events being
grade I or II (Paccagnella et al, 1994; Domenge et al, 2000). Despite
inducing locoregional control, high response rates and a
significant improvement in survival, PF induction therapy is
associated with a relatively poor absolute rate of patient survival,
which is similar to that seen with intensive chemoradiotherapy
regimens (Paccagnella et al, 1994; Lefebvre et al, 1996; Domenge
et al, 2000; Pignon et al, 2000). The dose-intensive cisplatin–5-
FU–leucovorin (PFL) combination was subsequently developed in
an attempt to improve complete response rates to induction
chemotherapy and thus survival. The addition of leucovorin
resulted in higher complete response rates at the expense of
increased toxicity (Vokes et al, 1990; Schneider et al, 1995; Clark
et al, 1997).
The need for further improvements in SCCHN care has
stimulated intensive investigation into new agents with potential
in induction chemotherapy and chemoradiotherapy regimens.
New agents such as epidermal growth factor receptor (EGFR)
inhibitor ZD1839 (Iressat), antibody C225 (Cetuximabt) and
inhibitor OSI-774 (Tarcevat), in addition to farnesyl transferase
inhibitors, have shown some promise in early studies. Although
they are relatively ineffective as single agents, their combination
with other agents (radiation and/or cytotoxic drugs) is under
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5-FU and uracil) has shown promising single-agent activity, but
combination therapy has yet to be studied. Alpha interferon has
been tested as a potentiator of PFL or PF chemotherapy, but a
phase III trial has failed to demonstrate any additional advantages
from this approach (Vokes et al, 1995; Schrijvers et al, 1998).
Perhaps the most promising agents have been the taxanes. In
particular, the taxane docetaxel has demonstrated significant
single-agent activity in recurrent SCCHN (Catimel et al, 1994;
Dreyfuss et al, 1996; Couteau et al, 1999). Docetaxel is similar to
paclitaxel with respect to its general mechanism of action (tubulin
stabilization and cell cycle arrest), and the two share a number of
pharmacological characteristics (Colevas and Posner, 2001).
However, docetaxel and paclitaxel have somewhat different
pharmacodynamics and toxicities that may be important in
combination therapy programmes. Docetaxel, for example, has a
greater affinity for tubulin, a longer intracellular half-life, and
promotes microtubule stabilization at lower drug concentrations
(Lavelle et al, 1995). The major toxicity associated with docetaxel is
highly predictable myelotoxicity (Posner, 2001a). More impor-
tantly, neuropathy, a dominant side effect of cisplatin, is minimal
with docetaxel-containing regimens, but can be significant in
paclitaxel-containing regimens (Schrijvers and Vermorken, 2000;
Colevas and Posner, 2001; Posner, 2001a). The differing mechan-
isms of action, and relative nonoverlapping toxicities compared
with PF, have prompted interest in the addition of docetaxel to PF
regimens.
POTENTIAL OF DOCETAXEL IN SCCHN
In early preclinical studies, docetaxel demonstrated pronounced in
vitro and in vivo cytotoxicity against a variety of human cancer cell
lines, particularly head and neck cancer (Braakhuis et al, 1994). In
fact, docetaxel was more effective than cisplatin in inhibiting the
growth of two SCCHN xenograft models (HNX-14C and HNX-22B)
(Braakhuis et al, 1994). Further preclinical evidence for docetaxel
efficacy has been derived from studies employing a murine model,
representative of human head and neck cancer (Sommer et al,
2001). From the drugs investigated (cisplatin, carboplatin,
docetaxel, methotrexate, 5-FU), as single agents or in combination,
an ifosfamide–docetaxel combination produced the best tumour-
free survival.
The clinical efficacy and safety of docetaxel in SCCHN was
initially established in patients with metastatic or recurrent/
incurable SCCHN. In three phase II studies (Table 1), single-agent
docetaxel (100mgm
 2) administered on day 1 every 3 weeks
produced response rates ranging from 21 to 42% (Catimel et al,
1994; Dreyfuss et al, 1996; Couteau et al, 1999). As expected, grade
III–IV neutropenia was the principal toxicity in these studies.
These results compare favourably with other single agents in the
management of SCCHN (Schoffski et al, 1998; Posner, 2001a).
Phase I/II studies combining docetaxel with cisplatin and/or
5-FU were undertaken in recurrent or metastatic SCCHN patients
to look for improved efficacy and safety. In two trials, docetaxel–
5-FU resulted in ORRs of 24 and 27% (Colevas et al, 2000;
Tubiana-Mathieu et al, 2000). Docetaxel–cisplatin appeared to be
a more effective combination, with overall response rates ranging
from 33 to 76% (Kienzer et al, 1998; Schoffski et al, 1999; Specht
et al, 2000; Glisson et al, 2002). In the trial conducted by the
European Organisation for the Research and Treatment of Cancer
(EORTC), docetaxel (100mgm
 2) plus cisplatin (75mgm
 2)
produced a response rate of 54% (Schoffski et al, 1999). Of the
44 patients enrolled in this trial, 22 were chemotherapy-naı ¨ve and
the response rate in this group was 86%. As with single-agent
docetaxel, the main toxicity in each of the combination studies was
myelosuppression (Kienzer et al, 1998; Schoffski et al, 1999;
Colevas et al, 2000; Specht et al, 2000; Tubiana-Mathieu et al, 2000;
Glisson et al, 2002). Mucositis was more commonly seen in the
combination studies (particularly docetaxel–5-FU) than with
single-agent docetaxel.
DOCETAXEL INDUCTION THERAPY IN SCCHN:
PHASE II RESULTS
The promising response rates and tolerability profiles exhibited in
recurrent or metastatic SCCHN patients treated with docetaxel–
cisplatin led to the investigation of docetaxel regimens as
induction therapy for locally advanced disease. Two phase II
induction studies with docetaxel 75mgm
 2 plus cisplatin 75 or
100mgm
 2 i.v. every 3 weeks followed by definitive radiotherapy
in patients with locally advanced SCCHN have been reported (Mel
et al, 2000; Caponigro et al, 2001). In an intention-to-treat analysis,
objective responses of 62% and 46% were seen in patients during
the induction phase, with corresponding complete response rates
of 17% (Mel et al, 2000) and 11% (Caponigro et al, 2001),
respectively. Grade III–IV neutropenia was experienced by 74% of
patients in one study, although febrile neutropenia affected only
17% of patients (Mel et al, 2000). In the second study, 61% of
patients experienced grade III–IV neutropenia, which was
complicated by fatal sepsis in 2 (4%) patients (Caponigro et al,
2001). The authors suggest that these toxic deaths might have been
related to the higher dose of cisplatin (100mgm
 2) used in their
study (Caponigro et al, 2001). The incidences of grade III–IV
nonhaematological toxicity, including gastrointestinal complica-
tions, were relatively low in both studies. These results, in a
heterogeneous group of patients with moderate-to-poor perfor-
mance status, were similar to the data seen with PF. With data
from recurrent patients, these studies demonstrate that the
docetaxel–cisplatin combination has interactive efficacy similar
to that seen with PF.
Rather than substituting cisplatin or 5-FU with a newer SCCHN-
active agent such as docetaxel, in the curative setting, most
research is now focused on the addition of docetaxel to PF-based
regimens. Studies involving docetaxel–PF-based regimens de-
monstrate a high likelihood of superior clinical benefit vs current
treatment options in terms of response rate and survival.
Docetaxel plus modified PFL regimens
Three trials conducted at the Dana-Farber Cancer Institute
administered docetaxel with PFL in SCCHN patients with
advanced disease, who were potentially curable (Table 2) (Colevas
et al, 1998; 1999; 2002). In the first study, TPFL-5, 23 patients with
stage III–IV SCCHN received docetaxel 25–60mgm
 2 d1 (day 1),
cisplatin 25mgm
 2 d1–5, 5-FU 700mgm
 2 (N¼21) or
800mgm
 2 (N¼2) d2–5 and leucovorin 500mgm
 2 d1–5 every
4 weeks for three cycles (Colevas et al, 1998). The ORR prior to
definitive, twice daily radiation therapy was 100%, consisting of 14
Table 1 Phase II studies with single-agent docetaxel in patients with
SCCHN
Study
reference Dose/schedule
N (evaluable
patients)
Response
rate (%)
Catimel et al (1994) 100mgm
 2 37 32
d1 q3w
Dreyfuss et al (1996) 100mgm
 2 29 42
d1 q3w
Couteau et al (1999) 100mgm
 2 21 21
d1 q3w
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39%). Updated survival data (median follow-up 43 months)
revealed both the 3-year overall survival and disease-free survival
rates to be 78% (Posner et al, 2000). Approximately 40% of
patients receiving the maximum tolerated dose (MTD) of docetaxel
were hospitalised for neutropenia despite administration of
granulocyte colony-stimulating factor (G-CSF) d5–10 and cipro-
floxacin d5–15 (Colevas et al, 1998). Mucositis was the most
prominent grade III–IV nonhaematological toxicity (46% of
cycles), followed by nausea (11% of cycles) and diarrhoea (11%
of cycles). In all, 14 patients (61%) developed mild neuropathy
1–8 months after the first dose of chemotherapy.
In an attempt to reduce hospitalisation, the TPFL-4 regimen was
developed in which G-CSF was started earlier and treatment was
compressed into the first 4 days of the 4-week cycle (Colevas et al,
1999). In all, 30 stage III–IV SCCHN patients received two loading
doses of oral leucovorin 100mg followed by docetaxel (60mgm
 2)
d1 and then infusions of cisplatin (31.25mgm
 2day
 1), 5-FU
(700mgm
 2day
 1) and leucovorin (500mgm
 2day
 1) over 4
days. G-CSF was given d4–10 and ciprofloxacin on d5–15. The
ORR was 93%, with 63% CRs and 30% PRs. Primary tumour site
clinical and pathological responses were 93 and 68%, respectively.
The originally reported 2-year overall survival and disease-free
survival rates were 87 and 57%, respectively (Colevas et al, 1999).
A more recent analysis (median follow-up 30 months) reported the
2-year overall survival and disease-free survival rates as 83 and
53%, respectively (Posner et al, 2000). Haematological toxicity was
generally mild, with grade III–IV neutropenia, thrombocytopenia,
and anaemia reported during 8, 6 and 2% of cycles, respectively
(Colevas et al, 1999). Mucositis was the most prominent
nonhaematological grade III–IV event (48% of cycles), followed
by nausea/vomiting (15% of cycles). These values represent major
reductions in haematological and infectious toxicities compared
with patients in TPFL-5. As a result, hospitalization was reduced to
approximately 14%, the main cause of which was dehydration.
The op-TPFL trial, an outpatient study, represents a further
docetaxel–TPFL regimen modification (Colevas et al, 2002). The
objective of the study was to allow stage III–IV SCCHN patients to
receive TPFL chemotherapy at home with intensive nursing
support. Two doses of leucovorin 100mg were given as oral
loading. This was followed by docetaxel 60–95mgm
 2 d1,
cisplatin 100mgm
 2 d1, 5-FU 700mgm
 2 d1–4 and leucovorin
500mgm
 2 day 1–4 in a 3-week cycle. G-CSF and antibiotics were
administered, starting 6h after the end of chemotherapy. The MTD
of docetaxel was 90mgm
 2 with G-CSF support. The ORR was
94% and the CR 44% in the 34 treated patients. At a median follow-
up of 12 months, 27 (79%) patients were alive, with 18 (53%)
patients free of disease progression. Neutropenia and mucositis
were the most frequently observed toxicities. Of the 15 patient who
received 42 cycles administered at the MTD, grade III–IV
neutropenia and mucositis were observed in 15 (67%) and 5
(33%) patients, respectively. Febrile neutropenia occurred in
Table 2 Docetaxel plus modified PFL induction regimens for locally advanced SCCHN
Study
reference
Number of
patients
entered
Patient/disease
characteristics Regimen OR
a (%) CR
a (%)
Grade III–IV
toxicities
in X5% of
patients or
cycles (%)
Colevas et al
(l998)
Phase I/II
(n=24)
23 Previously untreated stage III or
nonmetastatic stage IV SCCHN
ECOG PS p2
TPFL-5: docetaxel 25–60mgm
 2 i.v. d1;
cisplatin 25mgm
 2day
 1 CIVI d1–5; 5-FU
700 or 800mgm
 2day
 1 CIVI d2–5;
leucovorin 500mgm
 2day
 1 CIVI d1–5
Repeat q4wk for up to three cycles,
followed by definitive BID RT
100 61 % of cycles at the MTD of
docetaxel 60mgm
 2 i.v. (n=45):
mucositis (46); neutropenia
(22); febrile neutropenia (22);
nausea (11); diarrhoea (11);
infection (7); renal tubular (7)
Colevas et al
(1999)
Phase II
(n=30)
30 Previously untreated stage III or
nonmetastatic stage IV SCCHN
ECOG PS p2
TPFL-4: docetaxel 60mgm
 2 i.v. d1;
cisplatin 31.25mgm
 2day
 1 CIVI d1–4;
5-FU 700mgm
 2day
 1 CIVI d1–4;
leucovorin 100mg oral LD 2 (6 and 12h
before docetaxel) then 500mgm
 2day
 1
CIVI day 1–4
Repeat q4wk for up to three
cycles, followed by definitive BID RT
93 63 % of TPFL-4 cycles: mucositis
(48); nausea/vomiting (15);
neutropenia (8); thrombocytopenia
(6); anorexia (6); diarrhoea (5);
infection (5); renal toxicity (5)
Colevas et al
(2002)
Phase I/II
(n=34)
34 Previously untreated stage III or
nonmetastatic stage IV SCCHN
ECOG PS 0 or 1
Outpatient TPFL: docetaxel
60–95mgm
 2day
 1 i.v. d1; cisplatin
100mgm
 2day
 1 i.v. d1; 5-FU
700mgm
 2d
 1 CIVI d1–4; leucovorin
100mg oral LD 2 then
500mgm
 2day
 1 CIVI d1–4
Repeat q3wk for up to three cycles in
responders, followed by definitive BID RT
94 44 % of patients at the MTD of
docetaxel 90mgm
 2 i.v. (n=15):
neutropenia (67); mucositis (33);
nausea (13); anorexia (13);
fatigue (13); febrile neutropenia (7);
thrombocytopenia (7); diarrhoea
(7); hepatotoxicity (7);
hyponatraemia (7); pain (7)
Abbreviations: SCCHN=squamous cell carcinoma of the head and neck; OR=overall response; CR=complete response; ECOG=Eastern Cooperative Oncology Group;
PS=performance status; TPFL=docetaxel/cisplatin/5-fluorouracil/leucovorin; i.v.=intravenously; 5-FU=5-fluorouracil; CIVI=continuous intravenous infusion; LD=loading dose;
RT=radiotherapy; MTD=maximum tolerated dose; BID=Twice Daily Hyperfractionated
aFor the evaluable population.
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op-TPFL is a viable clinical option.
Docetaxel plus PF regimens
The TPFL regimens are intensive and associated with considerable
toxicity. Patients routinely require G-CSF support and a significant
proportion are hospitalised either for treatment or for treatment-
related toxicity. In many patients age and comorbidities rule out
such dose-intensive chemotherapy regimens. Intermediate dose-
intensive regimens involving docetaxel in combination with PF
may be equally efficacious, providing alternatives in these patient
groups. Three trials in which this intermediate-dose approach was
investigated are discussed here and summarised in Table 3.
In the TAX 708 study, 43 chemonaı ¨ve patients with locally
advanced SCCHN received docetaxel 75mgm
 2 d1, cisplatin
75mgm
 2 (level I; N¼13) or 100mgm
 2 (level II; N¼30) d1
and continuous 5-FU 1000mgm
 2day
 1 d1–4 (Posner et al,
2001b). Ciprofloxacin was administered to all patients day 5–15
and G-CSF was permitted to manage febrile neutropenia or
treatment-delaying myelosuppression. The ORR was 93% and the
CR 40%. A complete clinical response was seen in 57% of
assessable tumours (Posner et al, 2001b). At a recent follow-up
(median 26 months), the 2-year overall survival rate was 82%
(Posner et al, 2001c). Of the grade III–IV toxicities, neutropenia
affected 95% of patients; however, febrile neutropenia and
infection affected only 19% and 2% of patients, respectively
(Posner et al, 2001b). Other grade III–IV toxicities include
stomatitis (30%), transient renal problems (30%), nausea (19%)
and diarrhoea (9%) (Posner et al, 2001b).
In a similar study (TAX 017HN), 48 patients with locally
advanced SCCHN received docetaxel 75mgm
 2 and cisplatin
75mgm
 2 (level I) or 100mgm
 2 (level II) d1, followed by
continuous infusions of 5-FU 750mgm
 2day
 1 over 5 days
(Schrijvers et al, 1999). Owing to infectious complications seen
in the first 18 patients, ciprofloxacin was added from d5 to 15.
Prior to this, six patients developed infections leading to
hospitalisation. Grade III–IV neutropenia was reported in 88
and 63% of patients in the level I and II groups, respectively. An
ORR of 71% was observed. At a recent follow-up (median 24
months), the 2-year overall survival rate was 42% (Posner et al,
2001c).
Janinis et al (2001) administered docetaxel 80mgm
 2 d1,
cisplatin 40mgm
 2 d2 and d3 and continuous 5-FU
1000mgm
 2day
 1 d1–3 every 4 weeks in chemonaı ¨ve patients
with locally advanced SCCHN. All patients received G-CSF d4–9.
A maximum of four chemotherapy cycles were allowed and
radiation therapy was planned after completion of chemotherapy.
The ORR postchemotherapy was 90% with a CR of 20%. After
radiotherapy, the ORR was 95% with a CR that increased to 73%.
After a median follow-up of 36 months, median disease-free and
overall survival had not been reached. The 2-year survival rate was
60%. Grade III–IV toxicity was limited to leucopenia (25%),
febrile neutropenia (10%), grade IV infection (10%) and grade IV
diarrhoea (5%). The most common acute nonhaematological
toxicities included alopecia, mucositis and peripheral sensory
neuropathy. Alopecia was reversible, and mucositis was mild
and did not require hospitalisation. Peripheral neuropathy was
seen in 25% of patients, but was of mild degree with late
occurrence.
ONGOING PHASE III INDUCTION STUDIES
INCORPORATING DOCETAXEL
It is apparent that docetaxel, when used in conjunction with
standard induction therapy (cisplatin, 5-FU with or without
leucovorin), has significant activity in locally advanced SCCHN.
Consistently high 2-year survival rates and ORRs have been
Table 3 Docetaxel plus PF induction regimens for locally advanced SCCHN
Study
Number of
patients
entered
Patient/disease
characteristics Regimen OR
a (%) CR
a (%)
Grade III–IV toxicities
in X5% of patients (%)
TAX 708
Posner et al
(2001b)
Phase I/II
(n=43)
43 Locally advanced SCCHN
ECOG PS 0 or 1
CT-naı ¨ve and no prior RT
or surgery for SCCHN
Docetaxel 75mgm
 2 i.v. d1; Cisplatin
75mgm
 2 or 100mgm
 2 i.v. d1;
5-FU 1000mgm
 2day
 1 CIVI d1–4
Repeat q3wk for up to three cycles,
followed by institution-specific definitive
therapy
93 40 Neutropenia (95); stomatitis (30);
hypomagnesaemia/hypocalcaemia
(30); febrile neutropenia (19);
nausea (19); diarrhoea (9);
vomiting (7); dehydration (7);
thrombocytopenia (5);
neurological-hearing (5);
liver enzyme abnormalities (5)
Janinis et al (2001)
Phase II
(n=20)
20 Locally advanced SCCHN
WHO PS 0–2
CT- and RT-naı ¨ve
Docetaxel 80mgm
 2 i.v. d1; Cisplatin
40mgm
 2 i.v. D2,3; 5-FU
1000mgm
 2day
 1 CIVI d1–3
Repeat q4wk for up to four cycles,
followed by definitive RT
90 20 Leucopenia (25); febrile
neutropenia (10);
Infection (10);
diarrhoea (5)
TAX 017HN
Schrijvers et al
(1999)
Phase I/II
(n=48)
48
b Locally advanced SCCHN
ECOG PS 0 or 1
No prior cancer treatment
Docetaxel 75mgm
 2 i.v. d1; Cisplatin
75mgm
 2 (level I) or 100mgm
 2
(level II) i.v. d1; 5-FU 750mgm
 2day
 1
CIVI d1–5
Repeat q3wk for up to four
cycles, followed by definitive RT
71 0 Level I (n=17): neutropenia (76);
infection (13); stomatitis (6);
diarrhoea (6)
Level II (n=11): neutropenia (63);
infection (18); stomatitis (9);
nausea (9); vomiting (9)
Abbreviations: SCCHN=squamous cell carcinoma of the head and neck; OR=overall response; CR=complete response; ECOG=Eastern Cooperative Oncology Group;
PS=performance status; CT=chemotherapy; RT=radiotherapy; i.v.=intravenously; 5-FU=5-fluorouracil; CIVI=continuous intravenous infusion; WHO=World Health
Organization; NR=not reported.
aFor the intention-to-treat population,
bUnpublished data.
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100%, respectively (Posner et al, 2001c). Each of the phase II
studies discussed has used a slightly different regimen with varying
concentrations of chemotherapy in 3- or 4-week cycles. The study
results have suggested somewhat different response rates, overall
survival rates and toxicity profiles. This may be attributed to
factors such as differences in patient selection or subtle differences
in schedule-related multidrug interactions.
Given the encouraging phase II experience with docetaxel
induction regimens, and the need to further investigate the various
regimens in a randomised, controlled setting, phase III studies of
two TPF-based regimens vs PF are warranted and are under way
(Posner et al, 2000). A phase III trial (TAX 324) is being conducted
mainly in the USA, with some centres in Europe and South
America. This trial is evaluating three cycles of TPF (docetaxel
75mgm
 2 d1, cisplatin 100mgm
 2 d1 and 5-FU 1000mgm
 2
d1–4 every 3 weeks) vs three cycles of PF (cisplatin 100mgm
 2 d1
and 5-FU 1000mgm
 2 d1–5 every 3 weeks). This trial comprises a
sequential therapy design incorporating postinduction chemora-
diotherapy. Patients in both arms are treated with definitive
chemoradiation, with weekly carboplatin for a maximum of seven
doses following induction chemotherapy. A second study con-
ducted by the EORTC (TAX 323) is evaluating four cycles of TPF
(docetaxel 75mgm
 2 d1, cisplatin 75mgm
 2 d1 and 5-FU
750mgm
 2 d1–5 every 3 weeks) vs four cycles of PF (cisplatin
100mgm
 2 d1 and 5-FU 1000mgm
 2 d1–5 every 3 weeks). A 7-
week course of radiotherapy is to commence within 4–7 weeks of
completing the last chemotherapy cycle. These ongoing, large-scale,
randomised trials are expected to confirm the positive benefits of
adding docetaxel to PF-based regimens, as already demonstrated in
the phase II setting.
DOCETAXEL-BASED CHEMORADIATION REGIMENS
FOR LOCALLY ADVANCED DISEASE
In recent controlled studies, PF-based chemoradiation regimens,
used as induction or definitive therapy, have demonstrated
improved efficacy compared with conventional or hyperfractio-
nated radiotherapy alone in locally advanced SCCHN (Vokes et al,
1995; Brizel et al, 1998). The activity of docetaxel in SCCHN,
coupled with the drug’s in vitro radiosensitizing properties
(Creane et al, 1999; Mason et al, 1999; Pradier et al, 2001),
provide the basis for clinical trials with docetaxel as a component
of concurrent or alternating chemoradiation in locally advanced
SCCHN (Koukourakis et al, 1999; Hesse et al, 2000; Tishler et al,
2002).
Docetaxel-based chemoradiation regimens have been shown to
be feasible and active as induction and adjuvant therapy. The
phase I/II study by Tishler et al (2002) considered daily radiation
concurrent with weekly docetaxel in 21 patients with stage III–IV
SCCHN, who responded poorly to induction chemotherapy, and
demonstrated an ORR of 86% (CR 57%). Radiation was delivered
at 2Gyday
 1, to a total dose of 66–74Gy. The MTD of weekly
docetaxel in this regimen was 25mgm
 2. Mucositis was the major
acute toxicity, occurring at grade III in all patients receiving
docetaxel 25mgm
 2. Swallowing problems represented the main
long-term toxicity, although no patient remained feeding-tube
dependent. Three-year survival was 460% in this poor prognosis
group of patients.
Chemoradiation therapies with docetaxel–cisplatin have
achieved an ORR as high as 100% (Varveris et al, 1999; Budach
et al, 2000). The chemoradiation protocol considered by Budach
et al (2000) was devised to reduce oral toxicity. A total of 15
patients with inoperable, recurrent head and neck cancer received
three cycles of docetaxel (50–60mgm
 2 d1) and cisplatin
(15mgm
 2 d2–5) during weeks 1, 4 and 7 alternating with two
courses of radiotherapy (5 2Gy; total dose 40Gy) in weeks 2–3
and 5–6. The recommended dose of docetaxel was 50mgm
 2,a s
60mgm
 2 led to unacceptable systemic toxicity in the first 12
patients treated. An ORR of 92% was achieved, with acceptable
levels of oral toxicity.
Varveris et al (1999) demonstrated that the radiosensitizing
effect of docetaxel–cisplatin on hyperfractionated radiotherapy
enables an ORR of 100% (CR 59%). Docetaxel and cisplatin were
both given at 30mgm
 2 twice weekly to 54 patients. This dose was
reduced to 15–20mgm
 2 because of severe acute toxicity in the
first 10 patients. Major toxicities included grade III–IV mucositis
(86%), grade I–III hypersensitivity reactions (11%) and grade III
myelotoxicity (11%).
Further studies are needed to elucidate the relative efficacy and
toxicity of these concurrent radiation regimens vs the traditional
sequential approach of induction chemotherapy followed by
definitive radiotherapy.
CONCLUSIONS
Unmet needs in SCCHN care have stimulated intensive investiga-
tion into new agents with potential in induction chemotherapy and
chemoradiotherapy regimens. Docetaxel has emerged as one of the
most active agents in SCCHN, and is particularly efficacious as a
component of induction therapy in locally advanced disease. The
results of phase II studies investigating TPF induction regimens
demonstrate consistently high 2-year survival rates and ORRs
across all trials, in the range of 42–82 and 71–100%, respectively
(Posner et al, 2001c). An acceptable toxicity profile is seen with
TPF-based regimens, with neutropenia and gastrointestinal
complaints accounting for the majority of adverse events. The
encouraging phase II results are being validated in the ongoing,
large-scale, randomised phase III studies comparing TPF with PF
regimens.
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